Cellular Biomedicine Group Inc Institutional Investor Sentiment Worsened in 2019 Q2

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Logo

Sentiment for Cellular Biomedicine Group Inc (NASDAQ:CBMG)

Cellular Biomedicine Group Inc (NASDAQ:CBMG) institutional sentiment decreased to 1.75 in 2019 Q2. Its down -0.25, from 2 in 2019Q1. The ratio dropped, as 21 investment managers increased and opened new positions, while 12 reduced and sold their positions in Cellular Biomedicine Group Inc. The investment managers in our partner’s database reported: 3.60 million shares, up from 3.15 million shares in 2019Q1. Also, the number of investment managers holding Cellular Biomedicine Group Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 9 Increased: 17 New Position: 4.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $285.33 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

The stock increased 2.07% or $0.3 during the last trading session, reaching $14.82. About 21,835 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has declined 34.49% since September 13, 2018 and is downtrending. It has underperformed by 34.49% the S&P500.

Analysts await Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to report earnings on November, 5. They expect $-0.73 EPS, down 30.36 % or $0.17 from last year’s $-0.56 per share. After $-0.63 actual EPS reported by Cellular Biomedicine Group, Inc. for the previous quarter, Wall Street now forecasts 15.87 % negative EPS growth.

Platinum Investment Management Ltd holds 0.26% of its portfolio in Cellular Biomedicine Group, Inc. for 672,885 shares. Awm Investment Company Inc. owns 80,165 shares or 0.25% of their US portfolio. Moreover, Nikko Asset Management Americas Inc. has 0.17% invested in the company for 532,318 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Sumitomo Mitsui Trust Holdings Inc., a Japan-based fund reported 528,418 shares.

More notable recent Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) news were published by: Seekingalpha.com which released: “Cellular Biomedicine readies equity offering – Seeking Alpha” on March 20, 2019, also Globenewswire.com with their article: “Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai – GlobeNewswire” published on October 25, 2018, Globenewswire.com published: “Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board – GlobeNewswire” on December 18, 2018. More interesting news about Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) were released by: Prnewswire.com and their article: “Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress – PRNewswire” published on April 30, 2019 as well as Globenewswire.com‘s news article titled: “Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes – GlobeNewswire” with publication date: November 06, 2017.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.